Ignite Creation Date:
2025-12-25 @ 2:04 AM
Ignite Modification Date:
2025-12-26 @ 12:29 AM
Study NCT ID:
NCT07151560
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-09-03
First Post:
2025-08-25
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial
Sponsor:
Renmin Hospital of Wuhan University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-08-30
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-08-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-08-30
Completion Date Type:
ESTIMATED
First Submit Date:
2025-08-25
First Submit QC Date:
None
Study First Post Date:
2025-09-03
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-25
Last Update Post Date:
2025-09-03
Last Update Post Date Type:
ESTIMATED